Revisão sistemática da terapia antiemética para quimioterapia emetogênica baixa: comparar antagonistas dos receptores 5-HT3 e dexametasona
OncologiaSobre o estudo
- Desenho
- Revisão sistemática
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- International journal of clinical oncology
- Publicado em
- 21 jul 2026
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Systematic review of antiemetic therapy for low emetogenic chemotherapy: comparing 5-HT3 receptor antagonists and dexamethasone
Takeshi Aoyama, Hirotoshi Iihara, Masakazu Abe, Makoto Wada, Keiko Iino, Tatsuo Akechi, Chiyo K Imamura, Ayako Okuyama, Keiko Ozawa, Yong-Il Kim et al.
Descritores MeSH
- Serotonin 5-HT3 Receptor Antagonists
- Antineoplastic Agents
- Dexamethasone
- Vomiting
- Antiemetics
- Nausea
- Neoplasms
- Humans
- Quality of Life
Veja também
Estudos relacionados
- Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology
- Randomized, double-blind phase III trial of a dexamethasone-free regimen for managing highly emetogenic chemotherapy-induced nausea and vomiting
- Comparative efficacy of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists with or without dexamethasone for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy (HEC): a network meta-analysis
- Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting